Skip to:

Medicine For All: The Case for a Public Option in the Pharmaceutical Industry

Dana Brown

Democratic, public ownership of pharmaceutical development, production, and distribution in the U.S. is necessary to combat the increasingly harmful impacts of Big Pharma which decades of regulation have failed to counteract. 

Too many Americans are suffering and dying prematurely because we have ceded control over a key part of our infrastructure for public health—the pharmaceutical industry—to unaccountable corporations, for whom the pursuit of profit trumps the needs of patients and communities. Instead of continuing to push the boulder of regulation up the hill in hopes that it one day finally proves effective, we can displace corporate power over our health and lives by moving towards a democratic, publicly-owned pharmaceutical sector, designed to respond to public health needs and deliver better health outcomes at lower costs.

Democratic, public ownership of pharmaceutical development, production, and distribution in the U.S. is necessary to combat the increasingly harmful impacts of Big Pharma which decades of regulation have failed to counteract.